Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8,225 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Sintilimab combined with bevacizumab in relapsed/persistent ovarian clear cell carcinoma (INOVA): an investigator-initiated, multicentre clinical trial-a study protocol of clinical trial.
Li R, Liu X, Song C, Zhang W, Liu J, Jiao X, Yu Y, Zeng S, Chi J, Zhao Y, Ma G, Huo Y, Li M, Peng Z, Li G, Jiang J, Gao QL. Li R, et al. Among authors: peng z. BMJ Open. 2022 May 24;12(5):e058132. doi: 10.1136/bmjopen-2021-058132. BMJ Open. 2022. PMID: 35613822 Free PMC article.
The first Chinese National Union of Real-world Gynaecological Oncology Research and Patient Management Platform: A retrospective study.
Zeng S, Chi J, Liu J, Jiao X, Liu X, Yu Y, Li R, Huo Y, Ma G, Zhao Y, Wang L, Zhou Q, Zou D, Cheng X, Li Q, Wang J, Yao S, Zhao W, Xia B, Chen Y, Fan J, Wang W, Hong L, Guo R, Liu Z, Gao Y, Li J, Zhang B, Yu J, Hu T, Zhang W, Shan W, Peng Z, Li M, Xie X, Ma D, Gao Q. Zeng S, et al. Among authors: peng z. BJOG. 2022 Nov;129 Suppl 2:60-69. doi: 10.1111/1471-0528.17328. BJOG. 2022. PMID: 36485066
Timing of interval debulking surgery and postoperative chemotherapy after neoadjuvant chemotherapy in advanced epithelial ovarian cancer: a multicenter real-world study.
Liu X, Zhao Y, Jiao X, Yu Y, Li R, Zeng S, Chi J, Ma G, Huo Y, Li M, Peng Z, Liu J, Zhou Q, Zou D, Wang L, Li Q, Wang J, Yao S, Chen Y, Ma D, Hu T, Gao Q. Liu X, et al. Among authors: peng z. J Ovarian Res. 2023 Jun 27;16(1):121. doi: 10.1186/s13048-023-01164-8. J Ovarian Res. 2023. PMID: 37370087 Free PMC article.
Exploratory biomarker analysis in the phase III L-MOCA study of olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer.
Li H, Peng Z, Zhu J, Zhao W, Huang Y, An R, Zheng H, Qu P, Wang L, Zhou Q, Wang D, Lou G, Wang J, Wang K, Kong B, Xie X, Yin R, Low J, Rozita AM, Sen LC, Meng YC, Kiong KS, Liu J, Liang Z, Lv W, Zhu Y, Hu W, Sun W, Su J, Wang Q, Zang R, Ma D, Gao Q. Li H, et al. Among authors: peng z. BMC Med. 2024 May 16;22(1):199. doi: 10.1186/s12916-024-03409-9. BMC Med. 2024. PMID: 38755585 Free PMC article. Clinical Trial.
Neoadjuvant PARPi or chemotherapy in ovarian cancer informs targeting effector Treg cells for homologous-recombination-deficient tumors.
Luo Y, Xia Y, Liu D, Li X, Li H, Liu J, Zhou D, Dong Y, Li X, Qian Y, Xu C, Tao K, Li G, Pan W, Zhong Q, Liu X, Xu S, Wang Z, Liu R, Zhang W, Shan W, Fang T, Wang S, Peng Z, Jin P, Jin N, Shi S, Chen Y, Wang M, Jiao X, Luo M, Gong W, Wang Y, Yao Y, Zhao Y, Huang X, Ji X, He Z, Zhao G, Liu R, Wu M, Chen G, Hong L; COCPO Consortium; Ma D, Fang Y, Liang H, Gao Q. Luo Y, et al. Among authors: peng z. Cell. 2024 Sep 5;187(18):4905-4925.e24. doi: 10.1016/j.cell.2024.06.013. Epub 2024 Jul 5. Cell. 2024. PMID: 38971151 Free article. Clinical Trial.
Sintilimab combined with bevacizumab in relapsed or persistent ovarian clear cell carcinoma (INOVA): a multicentre, single-arm, phase 2 trial.
Peng Z, Li H, Gao Y, Sun L, Jiang J, Xia B, Huang Y, Zhang Y, Xia Y, Zhang Y, Shen Y, Huang B, Nie J, Chen X, Liu X, Feng C, Li Z, Zhang W, Tao K, Zhang Q, Duan S, Chen Y, Chen Y, Wang W, Zheng H, Lu Y, Liu Y, Wang L, Qi W, He Y, Tian Y; NUWA Platform Research Group; Li G, Ma D, Gao Q. Peng Z, et al. Lancet Oncol. 2024 Oct;25(10):1288-1297. doi: 10.1016/S1470-2045(24)00437-6. Epub 2024 Sep 11. Lancet Oncol. 2024. PMID: 39276785 Clinical Trial.
8,225 results